Ieq Capital LLC Purchases 143 Shares of IQVIA Holdings Inc. $IQV

Ieq Capital LLC raised its stake in IQVIA Holdings Inc. (NYSE:IQV) by 0.3% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 41,664 shares of the medical research company’s stock after buying an additional 143 shares during the period. Ieq Capital LLC’s holdings in IQVIA were worth $7,345,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Sowell Financial Services LLC bought a new stake in shares of IQVIA in the 1st quarter valued at about $305,000. Mather Group LLC. grew its position in shares of IQVIA by 83.5% in the 1st quarter. Mather Group LLC. now owns 769 shares of the medical research company’s stock valued at $136,000 after buying an additional 350 shares during the last quarter. Private Advisor Group LLC grew its position in shares of IQVIA by 11.6% in the 1st quarter. Private Advisor Group LLC now owns 5,435 shares of the medical research company’s stock valued at $958,000 after buying an additional 566 shares during the last quarter. Park Avenue Securities LLC grew its position in shares of IQVIA by 40.4% in the 1st quarter. Park Avenue Securities LLC now owns 5,425 shares of the medical research company’s stock valued at $956,000 after buying an additional 1,562 shares during the last quarter. Finally, Wealth Enhancement Advisory Services LLC grew its position in shares of IQVIA by 34.5% in the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 13,259 shares of the medical research company’s stock valued at $2,338,000 after buying an additional 3,398 shares during the last quarter. Institutional investors own 89.62% of the company’s stock.

Analysts Set New Price Targets

IQV has been the topic of a number of analyst reports. Redburn Partners set a $188.00 price target on IQVIA in a research report on Friday, May 23rd. UBS Group boosted their price objective on IQVIA from $185.00 to $225.00 and gave the company a “buy” rating in a research note on Wednesday, July 23rd. Truist Financial boosted their price objective on IQVIA from $209.00 to $235.00 and gave the company a “buy” rating in a research note on Wednesday, July 23rd. Citigroup reissued a “neutral” rating on shares of IQVIA in a research note on Thursday, May 22nd. Finally, Robert W. Baird boosted their price objective on IQVIA from $159.00 to $196.00 and gave the company a “neutral” rating in a research note on Wednesday, July 23rd. Seventeen investment analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $228.62.

Insider Activity at IQVIA

In other IQVIA news, insider Keriann Cherofsky sold 549 shares of the stock in a transaction that occurred on Wednesday, July 23rd. The stock was sold at an average price of $191.53, for a total value of $105,149.97. Following the transaction, the insider owned 2,910 shares in the company, valued at approximately $557,352.30. This represents a 15.87% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Eric Sherbet sold 5,800 shares of the stock in a transaction that occurred on Wednesday, July 23rd. The stock was sold at an average price of $190.05, for a total value of $1,102,290.00. Following the completion of the transaction, the insider owned 27,178 shares in the company, valued at approximately $5,165,178.90. The trade was a 17.59% decrease in their position. The disclosure for this sale can be found here. 1.60% of the stock is currently owned by corporate insiders.

IQVIA Stock Down 0.0%

Shares of NYSE:IQV opened at $188.73 on Friday. The business’s 50 day simple moving average is $176.32 and its two-hundred day simple moving average is $167.99. The firm has a market cap of $32.08 billion, a P/E ratio of 27.31, a PEG ratio of 2.07 and a beta of 1.30. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.84 and a current ratio of 0.84. IQVIA Holdings Inc. has a 52-week low of $134.65 and a 52-week high of $252.88.

IQVIA (NYSE:IQV) last announced its quarterly earnings results on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.77 by $0.04. The business had revenue of $4.02 billion for the quarter, compared to analyst estimates of $3.96 billion. IQVIA had a return on equity of 30.05% and a net margin of 7.88%.The company’s quarterly revenue was up 5.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.64 earnings per share. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. As a group, research analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.